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Outcomes of Venovenous Extracorporeal Membrane Oxygenation 
Support for Acute Respiratory Distress Syndrome in Adults
Dae  Sung  Ma,  M.D.,  Joon  Bum  Kim,  M.D.,  Sung-Ho  Jung,  M.D.,  Suk  Jung  Choo,  M.D., 
Cheol  Hyun  Chung,  M.D.,  Jae  Won  Lee,  M.D.
Background:  Despite improved managements for acute respiratory distress syndrome (ARDS), its mortality remains 
high. Extracorporeal membrane oxygenation (ECMO) has emerged as the final option for the treatment of ARDS 
unresponsive to conventional measures. This study describes our experiences of venovenous ECMO support for the 
treatment of ARDS. Materials and Methods: Between 2007 and 2010, 56 patients (aged 56.6±13.4 years, 43 
males) received venovenous ECMO for the treatment of ARDS. The detailed clinical records were retrospectively 
reviewed.  Results: Before the institution of ECMO support, 35 patients (55.4%) required nitric oxide inhalation, 35 
patients (55.4%) received continuous renal replacement therapy, and 20 patients (35.7%) were in shock status. The 
median duration of ECMO support was 164 hours (range, 5 to 1,413 hours). 27 (48%) patients could be success-
fully weaned from ECMO. Of them, 7 (13%) survived to discharge. On logistic regression analysis, a requirement 
for higher inspiratory pressure before ECMO support was the only significant factor that could predict ECMO wean-
ing failure. Conclusion: The outcome of venovenous ECMO support for the treatment of ARDS was suboptimal. 
Further improvements in outcomes should be made through the accumulation of experience and establishment of a 
standardized protocol for the management of ECMO.
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INTRODUCTION
Acute  respiratory  distress  syndrome  (ARDS)  is  a  serious 
condition  that  is  characterized  by  sudden-onset  severe  hypo-
xemia  and  diffuse  bilateral  pulmonary  infiltrates  [1].  Various 
causes  or  associated  conditions m a y  r e s u l t  i n  A R D S ,  i n c l u d -
ing  pneumonia,  aspiration,  sepsis,  massive  blood  transfusion, 
and  trauma.  Mortality  and  morbidity  rates  associated  with 
ARDS  have  improved  on  account  of  enormous  advances  in 
the  understanding  of  the  pathophysiology  of  ARDS  and  the 
development  of  more  effective  therapeutic  strategies  for 
ARDS.  However,  the  ARDS  mortality  rate  remains  high 
[2-4].
Recently,  interest  has  arisen  regarding  the  role  of  ex-
tracorporeal  membrane  oxygenatio n  ( E C M O )  a s  a  f i n a l  t r e a t -
ment  option  for  ARDS  unresponsive  to  conservative  mea-
sures.  Internationally,  several  previous  studies  have  demon-
strated  the  efficacy  of  ECMO  support  for  this  indication  [5]. 
However, in the Republic of Korea, no clinical study has yet 
analyzed  the  efficacy  of  ECMO  support  for  ARDS.
The  purpose  of  this  study  was  to  describe  our  experience 
with  venovenous  ECMO  support  for  ARDS  at  our  institution Dae Sung Ma, et al
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Table 1. Baseline characteristics of all patients who received 
ECMO support
Characteristics Values
No.  of  patients
Age  (yr)
Male
Body  weight  (kg)
Height  (cm)
BSA  (m
2)
Underlying  condition
Liver  cirrhosis
Hypertension
Diabeties  mellitus
Chronic  lung  disease
Chronic  renal  failure
Cause  of  definitive  ECMO  support
Pneumonia
ARDS  secondary  to  sepsis
Aspiration  pneumonitis
Postoperative  ARDS
Acute  interstitial  pneumonitis
Trauma
Pulmonary  thromboembolism
Pre-ECMO  ventilator  setting
Volume  control/pressure  control  (n)
PEEP  (mmHg)
Respiratory  rate  (/min)
Inspiratory  pressure  setting  (mmHg)
Laboratory  test  before  ECMO
pH
PaCO2  (mmHg)
PaO2 ( m m H g )
PaO2/FiO2
SaO2 ( % )
Lactic  acid  (mmol/L)
CRP  (mg/dL)
56
  5 6 . 6 ±13.4
    43  (76.8)
  6 4 . 2 ±13.3
164.9±8.1
    1.71±0.20
    22  (39.3)
    17  (30.4)
    13  (23.2)
    13  (23.2)
  2  ( 3 . 6 )
    30  (53.6)
      9  (16.1)
      7  (11.6)
  5  ( 8 . 9 )
  3  ( 5 . 4 )
  1  ( 1 . 8 )
  1  ( 1 . 8 )
10/46
  8 . 8 ±4.5
 2 6 . 7 ±5.5
 2 2 . 4 ±6.3
    7.23±0.14
60.9±21.9
  6 3 . 2 ±32.2
  6 4 . 2 ±33.0
  8 1 . 1 ±14.6
  3 . 3 ±3.1
    17.12±11.06
V a l u e s  a r e  p r e s e n t e d  a s  m e a n ±standard  deviation  or  number 
(%).
ECMO=extracorporeal  membrane  oxygenation;  BSA=body  sur-
face  area;  ARDS=acute  respiratory  distress  syndrome;  PEEP= 
positive  end  expiratory  pressure;  CRP=C-reactive  protein.
and to discuss ways to improve the outcomes associated with 
this  treatment  option.
MATERIALS AND METHODS
Between  January  2007  and  November  2010,  153  patients 
received  ECMO  support  for  the  treatment  of  respiratory 
failure.  Excluding  the  patients  who  required  venoarterial 
ECMO  support  due  to  concomitant  heart  dysfunction  resulted 
in  the  final  inclusion  of  56  subjects  who  were  treated  with 
venovenous ECMO support. A retrospective chart review was 
conducted  using  data  from  these  patients.
ECMO support was set up in the intensive care unit (ICU) 
in all cases. Heparin infusion was started intravenously before 
cannulation and was administered continuously to maintain an 
activated  clotting  time  of  160  to  200  seconds.  Antibiotics 
were given routinely and changed according to proven micro-
bial  infections.  ECMO  was  established  with  venous  drainage 
(17  to  28  Fr)  from  the  femoral  vein;  arterialized  blood  was 
returned to the contralateral femoral vein or right internal jug-
ular  vein  (17  to  22  Fr).  System  replacement  was  undertaken 
in  the  case  of  severe  plasma  leakage  from  the  oxygenator, 
decreased ECMO blood flow, evidence of hemolysis, or dete-
rioration  of  the  oxygenator  gas  exchange  function.
1) Data analysis
Categorical  variables  are  presented  as  frequencies  and  per-
centages,  and  continuous  variables  are  expressed  as  mean± 
standard  deviation  or  medians  with  ranges.  All  pre-ECMO 
demographic,  clinical,  and  laboratory  variables  were  assessed 
by a multiple logistic regression model to determine potential 
risk  factors  for  ECMO  weaning  failure  and  in-hospital  death. 
All  data  were  analyzed  using  SPSS  ver.  18  (SPSS  Inc.,  Chi-
c a g o ,  I L ,  U S A ) .
RESULTS
The  baseline  characteristics  of  the  patients  are  summarized 
in  Table  1.  Among  the  56  patients,  22  patients  underwent 
surgical intervention before ECMO support; the surgical inter-
ventions  included  liver  transplantation  in  13  cases  (23.2%), 
lung  resection  in  4  (7.1%),  open  heart  surgery  in  3  (5.4%), 
abdominal aorta replacement in 2 (3.6%), and colon resection 
in  1  (1.8%).  The  most  common  reason  for  ECMO  support 
was  pneumonia  (53.6%),  followed  by  ARDS  secondary  to 
sepsis  (16.1%).
The median duration of ICU stay and ventilator care before 
ECMO support was 5 days (range, 0 to 64 days) and 4 days 
(range,  0  to  37  days),  respectively.  Before  the  initiation  of Extracorporeal Membrane Oxygenation in Acute Respiratory Distress Syndrome
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Table 2. Murray lung injury score of all patients
Values
Murray  lung  injury  score
PaO2/FiO2 s c o r e
CXR  score
PEEP  score
Compliance  (mL/cmH2O)  score
3.1±0.4
3.3±0.5
3.4±0.9
1.9±1.4
3.5±0.7
Values  are  presented  as  mean±standard  deviation.  The  Murray 
score  is  a  grading  system  for  ARDS  which  uses  4  pieces  of 
information  graded  0−4  to  give  a  severity  index  for  ARDS. 
The  data  required  are:  1)  PaO2/FiO2:  ≥300=0,  225−299=1, 
175−224=2,  100−174=3,  <100=4;  2)  CXR:  normal=0,  1  point 
per  quadrant  infiltrated;  3)  PEEP:  ≤5=0,  6−8=1,  9−11=2,  12
−14=3,  ≥15=4;  4)  Compliance  (mL/cmH2O):  ≥80=0,  60−
79=1,  40−59=2,  20−39=3,  and  ≤19=4.
CXR=chest  X-ray;  PEEP=positive  end  expiratory  pressure;  ARDS= 
acute  respiratory  distress  syndrome.
ECMO  support,  35  patients  (55.4%)  required  nitric  oxide  in-
halation,  35  patients  (55.4%)  received  continuous  renal  re-
placement  therapy,  and  20  patients  (35.7%)  were  in  shock 
(systolic  blood  pressure  ＜90  mmHg).  The  patients’  respira-
tory  parameters  and  ventilator  settings  before  ECMO  support 
are  also  shown  in  Table  1.  The  most  common  pre-ECMO 
ventilator setting was the pressure control mode (82.1%), with 
hypoxemia  and  hypercarbia  being  the  predominant  feature, 
even  during  ventilator  support.
The  Murray  score  for  evaluating  acute  lung  injury,  which 
is  calculated from  the mean  PaO2/FiO2  ratio, positive  end-ex-
piratory pressure, compliance, and chest radiography, for each 
patient  is  shown  in  Table  2.  The  mean  Murray  score  was 
3.1±0.4. The median size of the draining and inflow catheters 
was  20  Fr  (range,  17  to  28  Fr)  and  18  Fr  (range,  17  to  22 
Fr), respectively. The median duration of ECMO support was 
164  hours  (range,  5  to  1,413  hours),  during  which  the  oxy-
genators  were  changed  0.95±1.48  times  for  each  patient.
Twenty-seven  patients  (48%)  could  be  successfully  weaned 
off  ECMO.  Of  these  patients,  7  (13%)  survived  and  were 
eventually  discharged.  In  mortality  cases,  causes  of  death 
were  septic  shock  (35%),  ARDS  (31%),  multiorgan  failure 
(22%),  heart  failure  (6%),  and  bleeding  (4%).  On  univariate 
analysis,  a  requirement  for  higher  inspiratory  pressure  before 
E C M O  s u p p o r t  w a s  t h e  o n l y  f a c t o r  t h a t  s i g n i f i c a n t l y  p r e -
dicted ECMO weaning failure, at 20.7±6.9 mmHg in patients 
with  weaning  success  compared  with  24.0±5.4  mmHg  in  pa-
tients with weaning failure (p=0.012). No predictive factor for 
in-hospital  death  was  identified  in  this  study.
DISCUSSION
This article describes a retrospective analysis of our clinical 
experience  with  venovenous  ECMO  support  in  adults  with 
ARDS  unresponsive  to  conventional  treatment.  This  report  is 
the  first  clinical  analysis  of  ECMO  for  ARDS  in  Korea.  In 
the  present  study,  the  ECMO  weaning  success  rate  was  48% 
( 2 7  o f  5 6  p a t i e n t s )  a n d  t h e  t o t a l  s u r v i v a l  t o  d i s c h a r g e  r a t e  
was  13%  (7  of  56  patients).  Compared  with  recent  reports, 
this  study  revealed  disappointing  results.  Hemmila  et  al.  [5] 
reported  their  experience  with  ECMO  support  for  ARDS  in 
255  adults  from  1989  to  2003.  Their  study  revealed  an 
ECMO weaning rate of 67% and a survival discharge rate of 
52%.  Their  survival  discharge  rate  for  venovenous  ECMO 
support  specifically  was  59.5%  [5].  A  recent  multicenter 
randomized  controlled  trial,  the  conventional  ventilation  or 
ECMO  for  severe  adult  respiratory  failure  trial  (‘CESAR  tri-
al’),  revealed  an  improvement  in  survival  without  severe  dis-
ability at 6 months in patients who received ECMO treatment 
compared  with  those  who  received  continued  conventional 
ventilation  [6].  Further,  a  previous  study  identified  several 
factors predictive of ECMO mortality, including advanced pa-
tient age, a pre-ECMO arterial blood pH of less than 7.18, an 
increased  duration  of  pre-ECMO  ventilation,  the  underlying 
cause of respiratory failure, and complications associated with 
ECMO.  Another  report  demonstrated  that  venovenous  ECMO 
is  as  reliable  as  venoarterial  ECMO  in  patients  with  no  evi-
dence  of  organ  failure,  apart  from  that  in  the  lungs  [7].
Our  poor  results  could  be  explained,  in  part,  by  the  rela-
tively liberal patient selection. In our hospital, 21 patients un-
derwent  prolonged  mechanical  ventilation  for  more  than  1 
week  before  ECMO  initiation,  and  all  of  these  patients  died. 
Additionally,  compared  with  previous  studies  that  have  dem-
onstrated  good  results  based  on  a  standardized  protocol  for 
disease  management,  our  institution  has  insufficient  experi-
ence  with  ECMO  management  and  has  no  well-established 
standardized protocol. With additional accumulated experience 
and  an  established  standardized  protocol  for  ECMO  support, Dae Sung Ma, et al
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better  outcomes  are  expected.
In  a  clinical  trial  of  ECMO  management,  Bonacchi  et  al. 
[8]  introduced  a  new  cannulation  strategy  for  the  venous 
ECMO  “x-configuration.”  They  suggested  that  their  new 
method  allows  for  higher  separation  between  blood  inflow 
and  outflow,  thus  reducing  recirculation  and  increasing  sys-
temic  oxygen  saturation  and  delivery  [8].  A  single  in-
stitution’s  experience  with  a  bicaval  dual  lumen  catheter  for 
adult venovenous ECMO has also been reported [9]. In order 
to  improve  outcomes  associated  with  venovenous  ECMO, 
more  such  novel  innovations  should  be  attempted  and 
investigated.
This study has some important limitations. First, this was a 
retrospective  analysis  of  nonrandomized  patients.  Second,  our 
study included only a small number of patients, and risk fac-
tor  analysis,  therefore,  could  not  be  adequately  performed.
CONCLUSION
The  outcome  of  venovenous  ECMO  support  for  the  treat-
m e n t  o f  A R D S  w a s  s u b o p t i m a l  i n  this  single  institution 
study.  Futher  improvements  in  outcomes  should  be  under-
taken  through  the  accumulation  of  experience  and  establish-
ment  of  a  standardized  institutional  protocol  for  the  manage-
ment  of  ECMO.
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